The study included 78 CRC patients. The overall mutation frequency of the KRAS gene at codons 12 and 13 was 33.3% (26/78). KRAS gene mutations were significantly associated with poor tumour differentiation and liver metastasis. (35.05 months versus 25.72 months) . Those with KRAS gene mutations at codons 12 or 13 did not have significantly different median survival times (25.69 months versus 20.67 months, respectively). CONCLUSIONS: These findings suggest that a high frequency of KRAS gene mutations exists in Chinese patients with CRC, and that such mutations are associated with poor survival, tumour differentiation and liver metastasis in CRC patients.
Introduction
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the world and is one of the most substantial health problems in China. 1 Although the incidence of CRC has historically been lower in China than in Western countries, it has increased rapidly in recent years. 2 The preferred treatment for CRC is surgery, because invasive cancers within the colon wall are most likely to be cured by surgical management; stage III or IV disease is treated with chemotherapy before or after surgery to reduce tumour metastasis, shrink tumour size or slow tumour growth. It has been reported that 5-fluorouracil (5-FU) regimens can produce median survival times of about 12 months for advanced CRC. 3 of which are in codon 12 (wild-type GGT) and codon 13 (wild-type GGC) of exon 1. 11, 12 The KRAS gene encodes a 21 kDa protein, which is a guanosine-5′-triphosphate (GTP)/ guanosine-5′-diphosphate (GDP) binding protein with GTPase activity, and is involved in transduction of mitogenic signals to link receptor tyrosine kinase activation to downstream effectors. After GDP binds to the p21 RAS protein it will convert it into an inactive form, losing its function for signal transduction. RAS gene mutations usually cause constitutive activation of RAS GTPase, leading to activation of the downstream signalling pathways and resulting in cell transformation and tumorigenesis. 13 Studies have demonstrated specific types of point mutations of the KRAS oncogene and different frequencies of such mutations in CRC: 14, 15 KRAS gene mutations in CRC have been stated to be 20 -50%. 16 As suggested by Bazan et al., 17 this wide range might be due to several factors such as the sensitivity and specificity of mutation detection methods, the small series of selected patients and environmental factors. In any event, detection of KRAS gene mutations has been evaluated as a marker for poor prognosis or treatment response in CRC patients. 18, 19 KRAS mutations were also shown to be significantly associated with response to cetuximab therapy. 20 Another study showed that serum KRAS mutations were associated with Dukes' stage D and cancer-related survival. 21 Additionally it has been reported that there was no association between KRAS mutations and tumour stage or cancerrelated survival. 22 Such data indicate that further studies are needed to understand the associations between KRAS mutations and clinical outcomes in patients with CRC.
In China, KRAS mutations have rarely been studied. Thus, the present study investigated KRAS gene mutations at codons Z Li, Y Chen, D Wang, et al. KRAS mutations in colorectal cancer 12/13 and the association between these point mutations and clinicopathological features in Chinese patients with CRC. In addition, follow-up data were collected from all patients and the prognostic value of KRAS gene point mutations was assessed.
Patients and methods

STUDY POPULATION
Consecutive patients with CRC (confirmed histologically by the Department of Pathology at The First Hospital of Jilin University, Changchun, Jilin, China), who underwent radical surgery at the Department of Gastrointestinal Surgery at The First Hospital of Jilin University between January 2008 and August 2010, were eligible for inclusion in this study. All patients were asked to participate voluntarily. Patients were excluded if they had not received postoperative chemotherapy or if they were < 25 or > 80 years old. After laparotomy, all patients received 5-FU plus cisplatin-based chemotherapy: 5-FU was given at a dose of 15 mg/kg by continuous intravenous (i.v.) infusion over 2 -8 h, repeated daily for 5 days per cycle; cisplatin was administered at a dose of 20 mg/m 2 by continuous i.v. infusion, repeated daily for 5 days per cycle. None of the patients received postoperative adjuvant therapy.
Immediately after tumours were surgically removed from each patient, tumour tissue samples were routinely fixed in 10% neutral-buffered formalin. These samples were processed as follows: dehydration in graded ethanol; clearing in xylene; embedding in paraffin blocks (using standard automatic processing and embedding equipment); preparation of 10µm thick sections. These sections were stained with haematoxylin & eosin (H&E) and reviewed by three experienced pathologists. Histologically, all CRC tumours were defined at stages I -IV, according to the tumour-node-metastasis (TNM) classification system developed by the International Union Against Cancer. 23 Patients' clinicopathological features were collected, including tumour growth pattern, tumour location, tumour differentiation, lymph node metastases and liver metastases.
The Ethics Committee of the Cancer Research Centre of Jilin University approved the study and all patients provided their individual written informed consent to participate.
DNA EXTRACTION AND DETECTION OF KRAS GENE MUTATIONS
Selection of paraffin blocks was based on the examination of one H&E-stained slide to ensure that the area of tissue and total number of cells were similar for the different CRC patient samples. Selected sections were then taken from regions of the tumour containing as high a proportion of tumour cells as possible (typically ≥ 60%), as identified by three experienced pathologists.
Genomic DNA was then extracted from three 10-µm sections for each tumour sample, according to protocols described previously. 24 Briefly, tissue sections were deparaffinized in xylene, washed in absolute ethanol and incubated at room temperature with 150 µl of digestion buffer (1 mg/ml proteinase K; 0.05 M Tris-HCl, pH 8.5; 1 mM ethylenediaminetetraacetic acid; 0.5% Tween 20; 2% sodium dodecyl sulphate) for 24 h, then centrifuged at 15 000 g for 15 min before DNA extraction with a QIAamp ® DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. After DNA had been obtained from the elution, its concentration was spectrophotometrically assessed at a wavelength of 280/260 nm, adjusted to a final concentration of 100 µg/ml Z Li, Y Chen, D Wang, et al.
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and stored at -20°C until use.
To detect KRAS gene mutations, polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) was performed using primers and a PCR kit purchased from Takara Biotechnology (Dalian) Co. Ltd, Dalian, China. Briefly, a 50-µl PCR mixture was prepared for each sample containing 2 µl of genomic DNA, 1 µl of 10 µmol/l of each primer and 25 µl premix (1.5 U Takara Taq polymerase, 10× PCR buffer, 3.0 mmol/l Mg 2+ and 0.4 mmol/l deoxynucleotide triphosphate). The primers to detect KRAS gene mutations at codons 12 and 13 were (forward) 5′-AGGCCTGCTG AAAATGACTGAATA-3′ and (reverse) 5′-CTGTATCAAAGAATGGTCCTGCAC-3′, as described previously. 25 PCR was performed on a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). An initial denaturing step was carried out at 94°C for 5 min, followed by 30 cycles at 94°C for 30 s, 60°C for 30 s and 72°C for 30 s, with a final extension step at 72°C for 5 min. The amplified PCR products were stored at 4°C until analysis. They were separated on 1.5% agarose gels and purified using a QIAquick ® PCR Purification Kit (Qiagen, Venlo, The Netherlands) and sent to Shanghai Generay Biotech Co. Ltd, Shanghai, China for DNA sequencing analysis of KRAS gene mutations ( Fig. 1 ).
SURVIVAL ANALYSIS
Overall survival was defined as the time from histopathological diagnosis to death from any cause. Patients were followed up until July 2011.
STATISTICAL ANALYSES
Statistical analyses were performed using the SPSS ® statistical package, version 17.0 (SPSS Inc., Chicago, IL) for Windows ® . Differences in categorical variables (such as gender, age, disease stage, differentiation, type of invasion, tumour localization, metastasis and TNM stage) between patients with or without KRAS mutations were evaluated with the χ 2 -test. Kaplan-Meier survival curves were constructed to evaluate the relationship between KRAS wild-type/mutation type and patient survival; Cox proportional hazards models were used for univariate and multivariate analyses of clinicopathological factors. A P-value < 0.05 was considered to be statistically significant. All statistical tests were two-sided.
Results
A total of 78 patients with CRC were recruited for the detection of KRAS gene mutations and their characteristics are shown in Table 1 . Patients were aged between 28 and 70 years and had tumours staged across all four stages of the TNM classification system. 23 Mutation of the KRAS gene at codons 12 or 13 were found in 26 patients (Table 2) , representing an overall mutation frequency 12 , the GGT to GAT transition (which leads to substitution of a glycine by aspartic acid) occurred in 13 cases, the GGT to GTT transition (which leads to the substitution of a glycine by valine) occurred in five cases and the GGT to GCT transition occurred in one case, leading to substitution of a glycine by alanine. The GGC to GAC change was the only transition to be found at codon 13 ( Table 2) ; this leads to substitution of a glycine by aspartic acid. Overall, the substitution of glycine by aspartic acid occurred at the highest frequency (76.9%, 20/26).
The KRAS gene mutations were associated with poor tumour differentiation (P < 0.05; Table 1 ) and liver metastasis (P < 0.05; Table  1 ). There were no statistically significant differences between KRAS gene mutations and other clinicopathological data (Table 1) . Survival data were available for all 78 patients. The median survival times were 35.05 months for patients with wild-type KRAS and 25.72 months for those with KRAS gene mutations; this difference was significant (χ 2 = 5.13, P = 0.023; Fig. 2A ). Patients with KRAS gene mutations at codon 12 or 13 had median survival times of 25.69 months and 20.67 months, respectively, which was not statistically significantly (Fig. 2B ). Univariate analysis showed that KRAS mutations were associated with poor prognosis in CRC patients (P = 0.023), whereas multivariate analysis (Table  3) showed that liver metastasis, KRAS gene mutation and poor tumour differentiation were independent factors for survival (P = 0.001, P = 0.007, and P = 0.026, respectively).
Discussion
Data obtained in the present study revealed a high frequency of KRAS gene mutations in Chinese patients with CRC. The predominant type of mutation was G→A transition followed by G→T transversion. Furthermore, KRAS gene mutations were associated with poor tumour differentiation and liver metastasis. The median survival time was shorter in CRC patients with KRAS gene mutations compared with those with wild-type KRAS. In contrast, the median survival times for patients with KRAS gene codon 12 or 13 mutations were similar.
It is known that KRAS gene mutations contribute to the early onset of CRC. 26 Such mutations mostly occur at codons 12 and 13, leading to the activation of RAS protein. Al-Mulla et al. 27 showed that the tightly bound complex of GTP to codon 12 glycine-tovaline mutant RAS protein generated a more stable signal to activate the downstream genes, compared with the codon 12 glycineto-aspartic acid mutant RAS protein. Thus, this KRAS gene mutation has been considered as an initiation factor for the development of CRC.
Data collected from patients of different ethnicities has shown that the frequency of KRAS gene mutations ranges from 30% to 60% in CRC: such data have come from studies conducted in the UK, 28 Slovenia, 29 Korea, 30 Switzerland, 31 USA 32 and The Netherlands. 26 These studies revealed the G→A transition as being the most frequent KRAS mutation type. Similarly, the G→A transition was the most frequent mutation observed in the present study. The G→A transition may occur spontaneously due to errors in DNA replication, 33 whereas both the G→A transition and the G→T transversion could be the result of dietary mutagens. 11 Associations between KRAS gene mutations and certain clinicopathological data have been reported previously, but findings have been inconsistent. For example, there was no association between KRAS gene mutations 34 Similar results were reported for 53 Turkish patients with CRC. 35 In contrast, an association between mutations in KRAS codon 13 and Dukes' stage in CRC patients has been demonstrated, 17 and KRAS mutations have also been found to be associated with Dukes' stage and microsatellite stable status in CRC. 36 Moreover, KRAS gene mutations were reported to be associated with patients' gender and CRC localization. 37 An association between KRAS gene mutations and gender in Chinese CRC patients has also been reported. 16 The current study showed associations between KRAS gene mutations, poor tumour differentiation and liver metastasis, which is in agreement with previous studies. 38, 39 To date, the causes of KRAS gene mutations are unknown.
Studies have shown conflicting results for the prognostic significance of KRAS mutations in CRC. Some have shown that the substitution of glycine with aspartic acid at codon 12 in the KRAS gene in patients with Dukes' stage C cancer, and the G→A mutation at codon 13, were both associated with poor survival. 18, 31 In contrast, other studies have not revealed any prognostic differences between wild-type and mutant KRAS. 40, 41 The present study showed that KRAS mutations significantly reduced the survival time of CRC patients compared with the survival time in those with wild-type KRAS. Although the median survival of patients with KRAS gene codon 12 mutations was longer than that for patients with KRAS gene codon 13 mutations after adjusting for gender, age, general condition, chemotherapy and surgical technique, there was no statistically significant difference in terms of survival with mutations in the two different codons. This finding, in particular, warrants further investigation in a larger study population.
Mechanistically, KRAS protein affects the downstream EGFR signalling pathway. Mutations in the KRAS gene lead to the constitutive activation of KRAS signalling pathways as a result of the loss of GTPase activity. 9 Increased EGFR and KRAS signalling is involved in CRC and tumour progression. 42 CRC patients with KRAS gene mutations are likely to have chemotherapy resistant disease which, in turn, results in a poor prognosis. Because mutations in the KRAS gene confer tumour resistance to anti-EGFR antibody therapy, assessing the KRAS mutational status in CRC patients is important for establishing the likelihood of therapeutic success. 9 Anti-EGFR antibody therapy improves survival in patients with metastatic CRC and wild-type KRAS; cetuximab is a human/mouse chimeric immunoglobulin-G 1 monoclonal antibody that binds to the extracellular domain of the EGFR and inhibits EGFR-mediated signalling. 43 Studies have demonstrated that patients with wildtype KRAS have better responses to cetuximab than those with KRAS gene mutations: 44, 45 the overall response rate of patients with wildtype KRAS to cetuximab is only 40 -60%, but the response rate in patients with KRAS gene mutations is 10% lower. 44, 45 Research in Chinese patients with CRC has also found that mutations in the KRAS and EGFR genes provide evidence for the efficacy prediction of EGFR-targeting therapeutic strategies. 37 These indicators are not, however, perfect predictors and are only relevant to the EGFR tyrosine kinase pathway. Other nontyrosine kinases may also be involved in EGFR signalling, which may explain why these indicators are not always able to predict therapeutic resistance. How different mutations of the KRAS gene affect the response of CRC patients In conclusion, the present study demonstrated that a high frequency of KRAS gene mutations was associated with poor tumour differentiation and liver metastasis, and that such mutations were associated with poor survival, in Chinese patients with CRC. Further studies are needed, to elucidate the underlying mechanisms.
